Secondary pooled analysis of the phase 3 SWIFT-1/-2 trials in type 2 asthma: depemokimab every 26 weeks cut the probability of a first exacerbation over 52 weeks by 46% vs placebo (HR 0.54, 95% CI 0.43–0.69), with effects from week 4.
Secondary analysis
Wechsler et al. Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies